Published in Comput Biol Chem on July 01, 2004
A comparative study of discriminating human heart failure etiology using gene expression profiles. BMC Bioinformatics (2005) 1.85
Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics (2011) 1.50
Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data. Nucleic Acids Res (2005) 1.19
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med (2005) 0.92
Comprehensive evaluation of matrix factorization methods for the analysis of DNA microarray gene expression data. BMC Bioinformatics (2011) 0.88
A novel method incorporating gene ontology information for unsupervised clustering and feature selection. PLoS One (2008) 0.84
Variability of DNA microarray gene expression profiles in cultured rat primary hepatocytes. Gene Regul Syst Bio (2007) 0.77
A survey of computational tools for downstream analysis of proteomic and other omic datasets. Hum Genomics (2015) 0.76
Semi-Supervised Projective Non-Negative Matrix Factorization for Cancer Classification. PLoS One (2015) 0.75
Multiclass prediction with partial least square regression for gene expression data: applications in breast cancer intrinsic taxonomy. Biomed Res Int (2013) 0.75
Gene selection for cancer classification with the help of bees. BMC Med Genomics (2016) 0.75
Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells. Sci Rep (2016) 0.75
Gene features selection for three-class disease classification via multiple orthogonal partial least square discriminant analysis and S-plot using microarray data. PLoS One (2013) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol (2006) 8.87
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
ISA software suite: supporting standards-compliant experimental annotation and enabling curation at the community level. Bioinformatics (2010) 5.60
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Toward interoperable bioscience data. Nat Genet (2012) 4.72
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
A strategy capitalizing on synergies: the Reporting Structure for Biological Investigation (RSBI) working group. OMICS (2006) 3.51
ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect (2003) 3.39
Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol (2006) 3.13
Identification of a salmonellosis outbreak by means of molecular sequencing. N Engl J Med (2011) 2.81
QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn (2004) 2.73
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Development of public toxicogenomics software for microarray data management and analysis. Mutat Res (2004) 2.29
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics (2008) 1.98
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89
Dedifferentiation and proliferation of mammalian cardiomyocytes. PLoS One (2010) 1.89
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
Spatial distribution of nerve sprouting after myocardial infarction in mice. Heart Rhythm (2006) 1.75
GOFFA: gene ontology for functional analysis--a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics (2006) 1.72
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
On the evolutionary history, population genetics and diversity among isolates of Salmonella Enteritidis PFGE pattern JEGX01.0004. PLoS One (2013) 1.69
DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res (2010) 1.69
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Differential beta-adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia. Heart Rhythm (2005) 1.58
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern Lab Anim (2005) 1.52
Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells (2010) 1.52
Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PLoS One (2011) 1.49
Gene expression profiling of cultured human islet preparations. Diabetes Technol Ther (2004) 1.42
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol (2011) 1.41
Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol (2002) 1.40
Next-generation sequencing in the clinic: promises and challenges. Cancer Lett (2012) 1.39
Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. PLoS One (2012) 1.36
Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn (2011) 1.33
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
Safety of upper-room ultraviolet germicidal air disinfection for room occupants: results from the Tuberculosis Ultraviolet Shelter Study. Public Health Rep (2008) 1.27
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J Nutr (2002) 1.27
Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos (2010) 1.27
mRNA enrichment protocols determine the quantification characteristics of external RNA spike-in controls in RNA-Seq studies. Sci China Life Sci (2013) 1.26
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. PLoS Comput Biol (2011) 1.26
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics (2005) 1.25
DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res (2011) 1.23
Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics (2012) 1.22
Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data. Nucleic Acids Res (2005) 1.19
Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX (2013) 1.19
Draft genome sequences of 21 Salmonella enterica serovar enteritidis strains. J Bacteriol (2012) 1.15
Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect (2004) 1.15
A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci (2012) 1.14
Overview of available methods for diverse RNA-Seq data analyses. Sci China Life Sci (2012) 1.13
Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci (2005) 1.12
Reproducibility Probability Score--incorporating measurement variability across laboratories for gene selection. Nat Biotechnol (2006) 1.12
Improvement in the reproducibility and accuracy of DNA microarray quantification by optimizing hybridization conditions. BMC Bioinformatics (2006) 1.12
Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model (2008) 1.09
Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem (2012) 1.09
Improving the power for detecting overlapping genes from multiple DNA microarray-derived gene lists. BMC Bioinformatics (2008) 1.09
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers (2006) 1.09
COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Res (2013) 1.08
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.08
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol (2011) 1.06
Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med (2013) 1.06
Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics (2014) 1.05
Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer (2010) 1.04
Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics (2006) 1.04
Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem (2003) 1.03
Targeted RNA-sequencing with competitive multiplex-PCR amplicon libraries. PLoS One (2013) 1.03
The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics (2010) 1.03
Transcriptome analysis reveals novel patterning and pigmentation genes underlying Heliconius butterfly wing pattern variation. BMC Genomics (2012) 1.02